Table 1.
Characteristics of study population of eribulin‐treated recurrent or metastatic breast cancer patients
| Treatment schedule | Total (n = 401) | Standard (n = 275) | Biweekly (n = 64) | Triweekly (n = 50) |
|---|---|---|---|---|
| Dose (mg/m2) | ||||
| Median | 1.4 | |||
| Range | 0.7‐1.4 | |||
| Age | ||||
| Median | 58 | 58 | 58.5 | 59 |
| Range | 26‐84 | 26‐81 | 33‐84 | 40‐74 |
| ECOG performance status (n) | ||||
| 0‐1 | 192 | 138 | 24 | 22 |
| 2 | 172 | 121 | 27 | 20 |
| ≥3 | 37 | 16 | 13 | 8 |
| Number of previous CTx regimens (n) | ||||
| 0 | 11 | 9 | 1 | 1 |
| 1 | 31 | 17 | 6 | 5 |
| 2‐4 | 194 | 127 | 33 | 28 |
| ≥5 | 165 | 122 | 24 | 16 |
| Serum albumin (g/dL) | ||||
| Median | 3.9 | 3.9 | 3.7 | 3.7 |
| Range | 1.3‐5.1 | 1.4‐5 | 1.7‐4.8 | 1.4‐4.8 |
| Baseline neutrophil count (/μL) | ||||
| Median | 3200 | 3432 | 3204 | 2972 |
| Range | 943‐15 000 | 943‐15 002 | 1090‐9430 | 1040‐6712 |
CTx, chemotherapy.